机构：[1]Leiden University Medical Center, Leiden, Netherlands[2]University Hospital of Essen (Ruhr), Essen, Germany[3]Clinic and Maternity Suizo Argentina, Buenos Aires, Argentina[4]Mount Sinai School of Medicine, New York, United States of America[5]RTI Health Solutions, Durham, United States of America[6]Beijing Anzhen Hospital, Beijing, China People’s Republic of首都医科大学附属安贞医院[7]Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, United States of America[8]Boehringer Ingelheim Ltd., Ontario, Burlington, Canada[9]Boehringer Ingelheim International GmbH, Ingelheim, Germany[10]Birmingham City Hospital, Birmingham, United Kingdom.
第一作者机构：[1]Leiden University Medical Center, Leiden, Netherlands
推荐引用方式(GB/T 7714)：
Huisman M. V.,Diener H. -C.,Dubner S. J.,et al.A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIA-AF Phase III baseline characteristics[J].EUROPEAN HEART JOURNAL.2018,39:825-825.
APA：
Huisman, M. V.,Diener, H. -C.,Dubner, S. J.,Halperin, J. L.,Rothman, K. J....&Lip, G. Y. H..(2018).A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIA-AF Phase III baseline characteristics.EUROPEAN HEART JOURNAL,39,
MLA：
Huisman, M. V.,et al."A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIA-AF Phase III baseline characteristics".EUROPEAN HEART JOURNAL 39.(2018):825-825
医学